Yesterday OncoLens, maker of a cancer care management platform, revealed that it snagged $1.35 million in seed funding. The round was led by BIP Capital and Atlanta Technology Angels (ATA).
The company also announced that Bill Midgette, board member of ATA, and Sarath Degala, VP at BIP Capital, will be joining OncoLens’ board.
WHAT THEY DO
The Atlanta-based company focuses on giving cancer care teams a way to collaborate on patients' treatment plans. The software-as-a-service tool, which includes a mobile application, is cloud based and HIPPA compliant.
The startup pitches its technology as an alternative to manually aggregating data from multiple caregivers. It has the ability to create annual schedules, as well as monitor and manage meetings.
Clinicians are able to upload images through a computer or iPhone. The technology also enables care teams to have real time discussions of cases, as an alternative to in person meetings. In addition, the platform can also screen patients for available clinical trials, and “provides cancer-specific decision support and assists cancer programs to track, discuss and implement nationally approved metrics.”
WHAT IT'S FOR
The new money is expected to help the company fulfill its strategic growth plans.
This isn't the only cancer-focused app on the market. In February of 2018, chemoWave, a chemotherapy companion app, was launched. The technology was designed to help chemotherapy patients manage their care, symptoms and side effects. Around the same time Witty Healthy launched OncoPower, which uses blockchain technology to help cancer patients keep track of their medical data across providers as well as offer users incentives.
In September Driver, a mobile app designed to link cancer patients to appropriate treatment or relevant clinical trials, launched. However, the tool, which had networks in both the United States and China, has since laid off all of its employees, effectively shuttering the business in mid-Ocober.
ON THE RECORD
“The Atlanta Technology Angels supports early-stage companies that have groundbreaking technologies,” Midgette said in a statement. “We are excited by the possibilities of the OncoLens software platform. Their solution allows academic and community based physicians to seamlessly integrate the volume of cancer data available today and the new therapies and diagnostics of tomorrow, thus optimizing the care path for their patients.”